CSL112 (Apolipoprotein A-I [Human]) Strongly Enhances Plasma Apoa-I and Cholesterol Efflux Capacity in Post-Acute Myocardial Infarction Patients: A PK/PD Substudy of the AEGIS-I Trial

• मुख्य लेखकों: C. Michael Gibson MS, MD (लेखक), Syed Hassan A. Kazmi MD (लेखक), Serge Korjian MD (लेखक), Gerald Chi MD (लेखक), Adam T. Phillips MD (लेखक), Sahar Memar Montazerin MD (लेखक), Danielle Duffy MD (लेखक), Bo Zheng PhD (लेखक), Mark Heise PhD (लेखक), Charles Liss MS (लेखक), Lawrence I. Deckelbaum MD (लेखक), Samuel D. Wright PhD (लेखक), Andreas Gille MD, PhD (लेखक)
• स्वरूप: पुस्तक
• प्रकाशित: SAGE Publishing, 2022-10-01T00:00:00Z.
• विषय: article
• ऑनलाइन पहुंच: Connect to this object online.

Introduction: Cholesterol efflux capacity (CEC) is impaired following acute myocardial infarction (AMI). CSL112 is an intravenous preparation of human plasma-derived apoA-I formulated with phosphatidylcholine (PC). CSL112 is intended to improve CEC and thereby prevent early recurrent cardiovascular...